VOLUME 111

AUTHOR INDEX

Abe, M. 381–387
Aengevaeren, W. R. M. 153–162
Agewall, S. 87–91
Al-Amri, M. 201–207
Ammons, M. C. B. 1–20
Andersen, N. H. 53–59
Ashman, N. 389–399
Askew, C. D. 401–409

Baldi, M. 71–80
Barden, A. E. 289–294
Barrett, P. H. R. 193–199
Beidleman, B. A. 163–169
Beilin, L. J. 289–294
Bhattacharya, S. 35–46
Bolbrinker, J. 365–372
Bonatti, J. 225–231
Brunini, T. M. 389–399

Calderone, A. 217–224
Cameron, J. D. 71–80
Caron, A. 217–224
Caterson, I. D. 281–287
Celermajer, D. S. 281–287
Chan, D. C. 193–199
Channer, K. S. 265–274
Chase, A. 233–249
Chen, S. 333–340
Chen, S.-J. 253–263
Chia, S. 275–280
Chu, M.-L. 253–263
Cianflone, K. 201–207
Cross, N. C. P. 233–249
Cruden, N. L. 275–280
Curi, R. 307–317
Cury-Boaventura, M. F. 307–317
Cymerman, A. 163–169

DeLeo, F. R. 1–20
Dell'Omo, G. 357–364
Del Prato, S. 357–364
Dinesen, D. S. 53–59
Döring, A. 365–372
Dover, A. R. 275–280
Dunstan, J. A. 289–294
Dupuis, J. 217–224

Edirisinghe, I. 145–151
Eiskjær, H. 53–59
Eldadah, B. A. 209–216
Erdmann, J. 365–372

Farouque, H. M. O. 71–80
Farthing, C. R. 35–46
Ferguson, J. W. 275–280
Fersterer, J. 225–231
Flyvbjerg, A. 53–59
Fotino, C. 357–364
Fox, K. A. A. 275–280
Fukuoka, T. 319–324
Fulco, C. S. 163–169

Gaffney, J. 171–183
Gamble, A. J. 47–52
Giannocco, G. 307–317
Glennie, M. J. 93–106
Goldstein, D. S. 209–216
Gosby, A. K. 281–287
Grattagliano, I. 135–143
Gray, J. C. 93–106
Green, S. 401–409
Gu, D. 333–340

Hahn, R. G. 127–134
Hammerer-Lercher, A. 225–231
Hansen, K. W. 53–59
Harbinson, M. T. 47–52
Helleberg, K. 53–59
Hense, H.-W. 365–372
Hernberg, Å. 87–91
Higaki, J. 319–324
Higashikata, T. 325–331
Hirata, Y. 381–387
Ho, L. M. L. 281–287
Hoefer, D. 225–231
Holmes, C. S. 209–216
Holzmann, S. 225–231
Hope, S. A. 71–80
Hsieh, S.-L. 253–263
Huang, W. 333–340
Hughes, S. 47–52

Iliescu, R. 251–252
Imig, J. D. 21–34
Imthurn, B. 81–86
Inazu, A. 325–331
Irawan, C. 81–86

Jansen, R. W. M. M. 153–162
Jasmin, J.-F. 217–224
Jensen, B. L. 61–70
Ji, J. 193–199
Johnson, A. G. 193–199
Johnson, P. W. M. 93–106
Jones, R. D. 265–274
Jones, T. H. 265–274

Kangawa, K. 381–387
Kappagoda, C. T. 145–151
Katsuda, S. 325–331
Kawashiri, M.-a. 325–331
Keizer, H. A. 119–126
Knudsen, S. T. 53–59
Kobayashi, J. 325–331
Komesaroff, P. 107–118
Kreutz, R. 365–372
Krupinski, J. 171–183
Kuipers, H. 119–126
Kumar, P. 171–183
Kumar, S. 171–183
Kuneš, J. 295–305
Kurata, M. 319–324
Kuse, S. 81–86

Lauterburg, B. H. 135–143
Leeners, B. 81–86
Lefebvre, F. 217–224
Leung, M. 71–80
Lewis, G. F. 185–187
Lewis, S. F. 163–169
Li, B. 333–340
Liao, C.-L. 253–263
Libby, P. 341–347
Lieb, W. 365–372
Lieverse, A. G. 119–126
Ling, S. 107–118
Lockhart, C. J. 47–52
Lucchesi, D. 357–364

Mabuchi, H. 325–331
MacDonald, S. T. 35–46
Mair, J. 225–231
Malkin, C. J. 265–274
Mallick, I. H. 373–380
Manders, R. J. F. 119–126
Mann, G. E. 389–399
Martins de Lima, T. 307–317
Mathias, C. J. 189–191
Matsuo, H. 381–387
McCormick Hallam, K. 145–151
McGivern, R. C. 47–52
McVeigh, G. E. 47–52
Meex, R. C. R. 119–126
Megson, I. L. 275–280
Mendes Ribeiro, A. C. 389–399
Meredith, I. T. 71–80
Michelsen, J. 61–70
Miwa, K. 325–331
Moak, J. P. 209–216
Mogensen, C. E. 53–59
Mori, T. A. 289–294
Muza, S. R. 163–169

Nagai, R. 381–387
Nagata, D. 381–387
Natal, C. 341–347
Neumaier-Wagner, P. 81–86
Newby, D. E. 275–280
Nishimatsu, H. 381–387
Nohara, A. 325–331
Nunes, M. T. 307–317
Nuzzo, R. 341–347
Nyström, T. 127–134

Okura, T. 319–324
Ooi, E. M. M. 193–199
Ottosen, P. D. 61–70

Palasciano, G. 135–143
Palmieri, V. O. 135–143
Pechnik, S. L. 209–216
Pedrinelli, R. 357–364
Penno, G. 357–364
Plumb, R. D. 47–52
Portincasa, P. 135–143
Poulsen, P. L. 53–59
Poulsen, S. H. 53–59
Praet, S. F. E. 119–126
Préfontaine, A. 217–224
Prescott, S. L. 289–294
Pucci, L. 357–364
Puschendorf, B. 225–231

Quinn, M. T. 1–20

Rath, W. 81–86
Rea, D. 47–52
Reckelhoff, J. F. 251–252
Remmen, J. J. 153–162
Ruttmann, E. 225–231
Rye, K.-A. 193–199

Saleem, A. M. 209–216
Sanderson, B. E. 401–409
Sata, M. 381–387
Sawka, M. N. 163–169
Schechter, C. 71–80
Schönbeck, U. 341–347
Schunkert, H. 365–372
Seifalian, A. M. 373–380
Sériès, F. 349–355
Sjöstrand, F. 127–134
Skilton, M. R. 281–287
Skøtt, O. 61–70
Skrinar, G. S. 163–169
Slevin, M. 171–183
Smith, J. 201–207
Sniderman, A. 201–207
Staab, J. E. 163–169
Stehouwer, C. D. A. 119–126
Stellaard, F. 135–143
Stevenson, M. 47–52
Stewart, I. B. 401–409
Stocker, R. 281–287
Su, S. 333–340
Sudhir, K. 107–118
Suzuki, E. 381–387
Sytwu, H.-K. 253–263

Takahashi, M. 381–387
Takata, M. 325–331
Takeda, R. 381–387
Thiesson, H. 61–70

van Loon, L. J. C. 119–126
Varo, N. 341–347
Verheugt, F. W. A. 153–162
Verin, E. 349–355
Villeneuve, L. 217–224

Walker, P. J. 401–409
Walter, S. 61–70
Wang, C.-C. 253–263
Wang, C.-J. 253–263
Wang, W. 349–355
Watanabe, S. 319–324
Watts, G. F. 193–199
Winslet, M. C. 373–380
Wolsley, C. 47–52
Wood, R. E 401–409
Wu, B. 281–287

Yamagishi, M. 325–331
Yang, W. 333–340
Yaqoob, M. M. 389–399

Zhao, W. 333–340
Zicha, J. 295–305

VOLUME 111

SUBJECT INDEX

Adrenaline
  β-blocker, tilt testing 189–191, 209–216
Adrenomedullin
  bone-marrow-derived cell, collateral development 381–387
  hypoxia, renal cell carcinoma 61–70
Airway dynamics
  breathing route, mouth opening 349–355
Angiogenesis
  ischaemic stroke, revascularization 171–183
Angiotensin 1-converting enzyme (ACE)
  gene polymorphism, hypertension 357–364
Angiotensin 1-converting enzyme 2 (ACE2)
  coronary heart disease, gender 333–340
Antitumour therapy
  immunotherapy, stimulatory monoclonal antibody 93–106
Aortic structure
  endothelial function, prenatal nutrition 281–287
Apolipoprotein B (apoB)
  body composition, vascular disease 201–207
  lipid transport protein, metabolic syndrome 185–187, 193–199
Arachidonic acid metabolite
  eicosanoid, renal vascular function 21–34
L-Arginine transport
  proximal tubular epithelial cell, system $b^{0,+}$ 389–399
Atherosclerosis
  cholesteryl ester transfer protein (CETP), familial hypercholesterolaemia 325–331
  hypertension, osteopontin 319–324

Bacterial meningitis
  non-typeable *Haemophilus influenzae*, Th1/Th2 response 253–263
β-Blocker
  neurally mediated hypotension, vasovagal syncope 189–191, 209–216
Blood flow velocity waveform
  nitric oxide, ophthalmic artery 47–52
Blood pressure
  n–3 fatty acid, pregnancy 289–294
Body composition
  apolipoprotein B (apoB), vascular disease 201–207
Body mass index (BMI)
  hypertension, pregnancy 81–86
Bone-marrow-derived cell
  adrenomedullin, collateral development 381–387
Breath test
  fatty liver, non-alcoholic steatohepatitis 135–143
Breathing route
  airway dynamics, mouth opening 349–355

Capillary permeability
  endothelial dysfunction, hypertension 357–364
Cardiovascular disease
  cellular mechanism, oestrogen 107–118
  environmental factor, genetic determinant 295–305
  fetal growth, prenatal nutrition 281–287
Cardiovascular risk
  cytokine, soluble CD40 ligand (sCD40L) 341–347
Cell death
  fatty acid, macrophage 307–317
Cellular homoeostasis
  NAPDH oxidase, reactive oxygen species 1–20
Cellular mechanism
  cardiovascular disease, oestrogen 107–118
Cholesteryl ester transfer protein (CETP)
  atherosclerosis, familial hypercholesterolaemia 325–331
Collateral development
  adrenomedullin, bone-marrow-derived cell 381–387
Congestive heart failure
  pulmonary renin–angiotensin system, structural remodelling 217–224
Continuous subcutaneous glucose monitoring
  glycaemic control, Type II diabetes 119–126
Coronary artery by-pass graft
  natriuretic peptide, vasorelaxation 225–231
Coronary artery disease
  flavanol-rich cocoa, vascular function 71–80
Coronary heart disease
  angiotensin 1-converting enzyme 2 (ACE2), gender 333–340
Cytochrome P450 3A (CYP3A)
  hypertension, left ventricular mass 365–372
Cytokine
  cardiovascular risk, soluble CD40 ligand (sCD40L) 341–347

Development
  myocardium, vasculature 35–46

Eicosanoid
  arachidonic acid metabolite, renal vascular function 21–34
Endothelial function
  aortic structure, prenatal nutrition 281–287
  smoking, statin 87–91

Endothelium-dependent relaxation
non-esterified fatty acid (free fatty acid), superoxide dismutase 145–151
Environmental factor
cardiovascular disease, genetic determinant 295–305
Exercise
peripheral arterial disease, vascular endothelial growth factor (VEGF) 401–409

Familial hypercholesterolaemia
atherosclerosis, cholesteryl ester transfer protein (CETP) 325–331
n–3 Fatty acid
blood pressure, pregnancy 289–294
Fatty acid
cell death, macrophage 307–317
Fatty liver
breath test, non-alcoholic steatohepatitis 135–143
Fenofibrate
metabolic syndrome, peroxisome-proliferator-activated receptor-α (PPAR-α) 185–187, 193–199
Flavanol-rich cocoa
coronary artery disease, vascular function 71–80

Gender
angiotensin 1-converting enzyme 2 (ACE2), coronary heart disease 333–340
Gene polymorphism
angiotensin 1-converting enzyme (ACE), hypertension 357–364
Genetic determinant
cardiovascular disease, environmental factor 295–305
Glycaemic control
continuous subcutaneous glucose monitoring, Type II diabetes 119–126

Haem oxygenase
ischaemia/reperfusion injury, multiple organ failure 373–380
Haematological malignancy
signal transduction therapy, tyrosine kinase 233–249
Heart failure
inducible nitric oxide synthase (iNOS), vascular tone 275–280
pulmonary capillary wedge pressure, Valsalva manoeuvre 153–162
testosterone, vascular reactivity 251–252, 265–274
Hydration
Type II diabetes, volume kinetics 127–134
Hypertension
angiotensin 1-converting enzyme (ACE), gene polymorphism 357–364
atherosclerosis, osteopontin 319–324
body mass index (BMI), pregnancy 81–86
cytochrome P450 3A (CYP3A), left ventricular mass 365–372
Hypoxia
adrenomedullin, renal cell carcinoma 61–70

Immunotherapy
antitumour therapy, stimulatory monoclonal antibody 93–106
Inducible nitric oxide synthase (iNOS)
heart failure, vascular tone 275–280
Intermittent altitude exposure
stress response, white blood cell 163–169
Ischaemia/reperfusion injury
pyrrolidine dithiocarbamate (PDTC), small bowel 373–380
Ischaemic stroke
angiogenesis, revascularization 171–183

Left ventricular mass
cytochrome P450 3A (CYP3A), hypertension 365–372
Lipid level
pregnancy, fish oil 289–294
Lipid transport protein
apolipoprotein B (apoB), metabolic syndrome 185–187, 193–199

Macrophage
cell death, fatty acid 307–317
Metabolic control
Type II diabetes, ventricular function 53–59
Metabolic syndrome
apolipoprotein B (apoB), lipid transport protein 185–187, 193–199
Mouth opening
airway dynamics, breathing route 349–355
Myocardium
development, vasculature 35–46

NAPDH oxidase
cellular homoeostasis, reactive oxygen species 1–20
Natriuretic peptide
coronary artery by-pass graft, vasorelaxation 225–231
Neurally mediated hypotension
β-blocker, vasovagal syncope 189–191, 209–216
Nitric oxide
blood flow velocity waveform, ophthalmic artery 47–52
Non-alcoholic steatohepatitis
breath test, fatty liver 135–143
Non-esterified fatty acid (free fatty acid)
endothelium-dependent relaxation, superoxide dismutase 145–151
Non-typeable *Haemophilus influenzae*
bacterial meningitis, Th1/Th2 response 253–263

Oestrogen
cardiovascular disease, cellular mechanism 107–118
Ophthalmic artery
blood flow velocity waveform, nitric oxide 47–52
Osteopontin
atherosclerosis, hypertension 319–324

Peripheral arterial disease
exercise, vascular endothelial growth factor (VEGF) 401–409
Pregnancy
blood pressure, *n*–3 fatty acid 289–294
body mass index (BMI), hypertension 81–86
Prenatal nutrition
aortic structure, endothelial function 281–287
Proximal tubular epithelial cell
L-arginine, transport system $b^{0,+}$ 389–399
Pulmonary capillary wedge pressure
heart failure, Valsalva manoeuvre 153–162

Pulmonary renin–angiotensin system
congestive heart failure, structural remodelling 217–224
Pyrrolidine dithiocarbamate (PDTC)
ischaemia/reperfusion injury, small bowel 373–380

Reactive oxygen species
cellular homoeostasis, NAPDH oxidase 1–20
Renal cell carcinoma
adrenomedullin, hypoxia 61–70
Renal vascular function
arachidonic acid metabolite, eicosanoid 21–34
Revascularization
angiogenesis, ischaemic stroke 171–183

Signal transduction therapy
haematological malignancy, tyrosine kinase 233–249
Small bowel
ischaemia/reperfusion injury, pyrrolidine dithiocarbamate (PDTC) 373–380
Smoking
endothelial function, statin 87–91
Soluble CD40 ligand (sCD40L)
cardiovascular risk, cytokine 341–347
Statin
endothelial function, smoking 87–91
Stimulatory monoclonal antibody
antitumour therapy, immunotherapy 93–106
Stress response
intermittent altitude exposure, white blood cell 163–169
Structural remodelling
congestive heart failure, pulmonary renin–angiotensin system 217–224
Superoxide dismutase
endothelium-dependent relaxation, non-esterified fatty acid (free fatty acid) 145–151
System $b^{0,+}$
L-arginine transport, proximal tubular epithelial cell 389–399

Testosterone
heart failure, vascular reactivity 251–252, 265–274
Th1/Th2 response
bacterial meningitis, non-typeable *Haemophilus influenzae* 253–263
Type II diabetes
continuous subcutaneous glucose monitoring, glycaemic control 119–126
hydration, volume kinetics 127–134
metabolic control, ventricular function 53–59
Tyrosine kinase
haematological malignancy, signal transduction therapy 233–249

Valsalva manoeuvre
heart failure, pulmonary capillary wedge pressure 153–162
Vascular disease
apolipoprotein B (apoB), body composition 201–207
Vascular endothelial growth factor (VEGF)
exercise, peripheral arterial disease 401–409
Vascular function
coronary artery disease, flavanol-rich cocoa 71–80
Vascular reactivity
heart failure, testosterone 251–252, 265–274
Vascular tone
heart failure, inducible nitric oxide synthase (iNOS) 275–280
Vasculature
development, myocardium 35–46
Vasorelaxation
coronary artery by-pass graft, natriuretic peptide 225–231
Vasovagal syncope
β-blocker, neurally mediated hypotension 189–191, 209–216
Ventricular function
metabolic control, Type II diabetes, 53–59
Volume kinetics
hydration, Type II diabetes 127–134

White blood cell
intermittent altitude exposure, stress response 163–169